CD8A and neoplasm: Blocking the METTL1–TGF-β2–PMN-MDSC axis (e.g., via anti-Ly6G antibody, hepatocyte-specific METTL1 or Tgfb2 knockdown, or inhibition of TGF-β signaling) markedly attenuates iRFA-induced tumor progression and restores CD8+ T cell levels (9).